Articles On Zelda Therapeutics (ASX:ZLD)

Title Source Codes Date
Hidden Gems Webinar Recap – ZLD, WTL, AGN, CLA

ShareCafeHidden Gems Webinar Recap – ZLD, WTL, AGN, CLA Catch up on the full webinar with presentations from  Zelira Therapeutics (ASX: ZLD), Argenica Therapeutics (ASX:AGN), WT Financial Group (ASX: WTL) & Celsius Resources Limited (...

ShareCafe ZLD 2 weeks ago
Market highlights and 5 ASX small caps to watch on Monday

Wall Street at fresh record highs All three key US benchmarks rose and reached fresh record highs on Friday, ahead of kick-off in earnings season. The Dow Jones was up by 1.30%, S&P 500 by 1.13%, and tech heavy Nasdaq by 0.98%. Bank sto...

Stockhead ZLD 2 weeks ago
Blazing it? How the top ASX cannabis shares performed in FY21

The 2021 financial year was overall a very good one for ASX shares. The S&P/ASX 200 Index (ASX: XJO) managed to put on a performance of 24% for the 12 months to 30 June 2021. That makes FY2021 one of the best financial years ever for t...

Motley Fool ZLD 3 weeks ago
Cannabis stocks celebrate Pershing ownership change

Cannabis stocks have welcomed the change in ownership of Pershing Australia from Bank of New York Mellon (BNYM) to Finclear Pty Ltd which – effective immediately – will allow the trading of cannabis securities on the ASX. In late 2019, BNYM...

Stockhead ZLD 3 weeks ago
Weed Week: Connecticut and Mexico on board cannabis bandwagon, as Rinehart enters the industry

Connecticut has become the latest US state to legalise recreational use of marijuana. The state’s governor has just signed a bill to allow people aged 21 and older to possess and consume marijuana, making it the 19th US state to do so. Here...

Stockhead ZLD 3 weeks ago
Weed Week: Amazon all-in on marijuana; free joints for jabs and Creso Pharma dual-listed in US

The US cannabis sector received a big lift after Amazon announced that job applicants at its offices and warehouses will no longer be drug-tested for marijuana use. Delivery drivers, however, will still be tested. The company also said it w...

Stockhead ZLD 1 month ago
Last Orders: ASX gains nearly 1 per cent back from the long weekend

The ASX 200 just closed 0.92 per cent up at 7,380 points  —  a new record high. The ASX Emerging Companies Index however fell 1.66 per cent, closing at 2,180. The best sector on the ASX was health which gained over 2 per cent while consumer...

Stockhead ZLD 1 month ago
Market highlights and 5 ASX small caps to watch on Tuesday

Wall Street mixed ahead as Nasdaq hits record highs Major indices in the US were mixed on Monday, with tech stocks leading the way, ahead of Thursday’s US Fed key policy meeting. The Dow Jones fell by 0.25%, S&P 500 rose by 0.18%, and t...

Stockhead ZLD 1 month ago
Building an export industry for cannabis medicines

The medicinal cannabis industry is gaining significant momentum, however, still remains in the early stages of growth. Zelira Therapeutics recently reported record quarterly cash receipts for the third quarter, up 249 per cent on H1 FY21. F...

Montgomery ZLD 1 month ago
Five ASX penny stocks making positive moves today

Summary Hillgrove Resources’ share price has skyrocketed 64.8% today and is currently trading at AU$0.089. Today, Veris’ share has given a breakout from a consolidation phase on the chart. The Red Sky Energy share price is also runnin...

Kalkine Media ZLD 2 months ago
Why are ASX healthcare shares Rhythm Biosciences and Zelira on the rise today?

Summary Diagnostics company Rhythm Biosciences has confirmed that LRF enhancements have shown to improve ColoSTAT® results. Cannabis medicines developer Zelira Therapeutics has entered into a partnership with Alternative Solutions for...

Kalkine Media ZLD 2 months ago
Why the Zelira (ASX:ZLD) share price is storming 7% higher

The Zelira Therapeutics Ltd (ASX: ZLD) share price is firmly in the green today following a positive update for its HOPE products. At the time of writing, the cannabis company’s shares are swapping hands for 5.7 cents, up 7.55%. What did Z...

Motley Fool ZLD 2 months ago
Market highlights and 5 ASX small caps to watch on Thursday

Dow Jones at record level, as US tech stocks sell off again The Dow Jones index has reached its all-time high, rising by 0.29% to finish at a record 34,230. However, tech stocks sold off again, with the likes of Amazon and Facebook falling...

Stockhead ZLD 2 months ago
How did Splitit Payments (ASX:SPT) fare in Q1 FY21?

Summary ASX-listed Splitit Payments Limited announced strong growth in Merchant Sales Volume (MSV) and revenue in Q1 FY2021. The Company’s brand awareness increased during the quarter, evident by the 70K increase in new shoppers. The...

Kalkine Media ZLD 3 months ago
Zelira (ASX:ZLD) share price falls despite strong trading update

The Zelira Therapeutics Ltd (ASX: ZLD) share price is lower during mid-afternoon trade despite announcing a positive trading update. At the time of writing, the cannabis company’s shares are fetching for 5.9 cents, down 1.67%. Q3 FY21 quar...

Motley Fool ZLD 3 months ago
Zelira announces record revenue in the march quarter

Zelira Therapeutics (ASX:ZLD) says it generated record quarterly product sales and licensing revenues of $225,000 for the March 2021 quarter, up 249 per cent from the previous six months.

BiotechDispatch ZLD 3 months ago
Market highlights and 5 ASX small caps to watch on Thursday

Wall Street mixed, even as banks’ earnings beat estimates US investors took the strong banks’ earnings in stride, with the major US indices petering out to a mixed finish. Major banks Goldman Sachs, JP Morgan and Wells Fargo unveiled quarte...

Stockhead ZLD 3 months ago
What will Elite Cannabinoids mean for ASX cannabis shares?

In what may be a catalyst for ASX cannabis shares, a private company today gained approval to grow medicinal cannabis in Western Australia. As reported by the ABC, the private medicinal cannabis company Elite Cannabinoids has received appr...

Motley Fool ZLD 5 months ago
The sector that’ll grow 480% this year, expert says

There is a sector in Australia that’s about to grow its revenue by 478% in the current financial year, according to one analyst. Consumer research firm IBISWorld revealed Tuesday that the medical cannabis manufacturing industry is currentl...

Motley Fool ZLD 6 months ago
5 top ASX cannabis shares in 2020

Investors in ASX cannabis shares have had a bumpy ride in 2020. Share prices were impacted by global oversupply issues in late 2019 then plunged in the March 2020 market downturn. But the Australian medical marijuana industry is building...

Motley Fool ZLD 7 months ago
Zelira Therapeutics Share Price Soars on Distribution Agreement

The share price of medical cannabis company Zelira Therapeutics Ltd (ASX:ZLD) has rocketed today thanks to a distribution agreement in the Washington DC area, US. At time of writing the ZLD share price is up 36.36% or 3.6 cents to trade at...

MoneyMorning ZLD 7 months ago
Here’s why the Zelira (ASX:ZLD) share price just rocketed to a new high

The Zelira Therapeutics Ltd (ASX: ZLD) share price is breaking new records today. This comes after the company announced a new licencing agreement with Alternative Solutions LLC. Alternative Solutions is a licenced grower, manufacturer and...

Motley Fool ZLD 7 months ago
Zelira shares soar after expanding US medical pot distribution

Shares in Zelira Therapeutics (ASX:ZLD) have risen more than 30 per cent to a nearly two-year high in early trade ... Read More The post Zelira shares soar after expanding US medical pot distribution appeared first on Stockhead.

Stockhead ZLD 7 months ago
Zelira Therapeutics’ (ASX:ZLD) September Quarter celebrates key milestones

Summary During September quarter, Zelira Therapeutics achieved significant milestones marking its successful transition to the ‘Launch, Learn and Develop’ model. Key developments include the launch of Zenivol™ in Australia and HOPE™ in...

Kalkine Media ZLD 7 months ago
Zelira Therapeutics (ASX:ZLD) sinks its teeth into US Oral Care Market with CBD toothpaste

Summary Zelira Therapeutics forays into the US oral care market by launching CBD toothpaste in partnership with US-based SprinJene®. The new CBD toothpaste will be Zelira’s first Over-the-Counter formulation. Further, the discussions...

Kalkine Media ZLD 7 months ago
Zelira Therapeutics, Emyria join hands to trial HOPE™ Products for Autism patients

Summary Leading biopharmaceutical company Zelira Therapeutics signed an agreement with Emyria Ltd for Autism Observational Trial of HOPE™ products. The Trial will collect efficacy and safety data from patients diagnosed with ASD and ha...

Kalkine Media ZLD 8 months ago
Drawbacks of the TGA’s cannabis changes for listed pot stocks

Having been subject to a harsh reality check over the last year or so, the ASX-listed cannabis sector is applauding the local medicine regulator’s endorsement of the weed as an effective therapy that should be more freely available to the a...

SmallCaps ZLD 10 months ago
ScoPo’s health powerplays: Pot stocks get a boost

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes for the week It’s been...

Stockhead ZLD 10 months ago
Zelira to launch new hemp-derived toothpaste in the US

Listed cannabis company Zelira Therapeutics (ASX: ZLD) has today formed a new Oral Care products subsidiary, tasked with selling a hemp-derived cannabinoid-based toothpaste. The company plans on launching the toothpaste product in the USA...

BusinessNewsAus ZLD 10 months ago
Zelira to launch new hemp-derived toothpaste in the US

Listed cannabis company Zelira Therapeutics (ASX: ZLD) has today formed a new Oral Care products subsidiary, tasked with selling a hemp-derived cannabinoid-based toothpaste. The company plans on launching the toothpaste product in the USA...

BusinessNewsAus ZLD 10 months ago
Zelira Therapeutics (ASX:ZLD) launches oral care subsidiary in US

08 Sep 2020 - Global therapeutic medicinal cannabis company, Zelira Therapeutics (ASX:ZLD) has expanded into the dental health market by launching a scientifically formulated, hemp…

FNN ZLD 10 months ago
Scopo’s powerplays: Investors love an ice queen

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week With repor...

Stockhead ZLD 11 months ago
Health Kick: Zelira’s cannabis-derived insomnia treatment has investors dreaming

Stockhead’s resident Health and Biotech expert Tim Boreham is putting down the pen and picking up the microphone for another instalment of The Health Kick Podcast. In this episode Tim chats with Dr Richard Hopkins, Managing Director of Zeli...

Stockhead ZLD 11 months ago
Scopo’s powerplays: Strap yourselves in for some M&A

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week The pundit...

Stockhead ZLD 11 months ago
Zelira partners with US research centre to treat symptoms of diabetes complications

Zelira (ASX: ZLD) has partnered with US-based Cardiovascular Solutions of Central Mississippi (CVSCM) to develop and commercialise CBD and hemp products to target symptoms associated with Peripheral Arterial Disease (PAD) and Diabetic Neuro...

BusinessNewsAus ZLD 1 year ago
Zelira Therapeutics targets arterial disease and diabetic illnesses with medicinal cannabis

Medical cannabis company Zelira Therapeutics (ASX: ZLD) has committed to a binding five-year agreement with US-based company Cardiovascular Solutions of Central Mississippi (CVSCM) to develop and commercialise products to treat symptoms ass...

SmallCaps ZLD 1 year ago
Scopo’s health powerplays: quick vaccine hits and cheap buys

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week The market...

Stockhead ZLD 1 year ago
Pot stock Zelira Therapeutics successfully passes another Phase I clinical trial

Zelira Therapeutics (ASX:ZLD) has completed another medicinal cannabis trial and passed with flying colours. This time it was a Phase 1 dose escalation study assessing the safety of its cannabis formulation in chronic pain patients using op...

Stockhead ZLD 1 year ago
Scopo’s health powerplays: You’re all going to the pot, literally

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week As markets...

Stockhead ZLD 1 year ago
COVID-19 hasn’t hurt cannabis clinical trials … much

Since the start of March, six clinical trials involving cannabis treatments around the world have been halted or cancelled altogether due to COVID19 pandemic but 179 are still recruiting, according to the US registry ClinicalTrials.com. Mor...

Stockhead ZLD 1 year ago
Zelira Therapeutics inks manufacturing deal with TasAlk

Australian medicinal cannabis company Zelira Therapeutics (ASX:ZLD) has announced a commercial supply agreement with Tasmanian Alkaloids (TasAlk) to manufacture the Insomnia and HOPE medicinal cannabis formulations.

BiotechDispatch ZLD 1 year ago
Zelira Therapeutics says ZLT-101 on track to launch later this year

Perth-based medicinal cannabis company Zelira Therapeutics (ASX:ZLD) has announced it has demonstrated its formulation ZLT-101 works for people suffering insomnia. 

BiotechDispatch ZLD 1 year ago
Zelira Therapeutics reveals more positive results from medical cannabis trial to treat insomnia

Zelira Therapeutics (ASX: ZLD) has announced its Phase 1b/2a medicinal cannabis trial to treat insomnia has met both its primary and secondary endpoints. The company today confirmed it has received the final clinical report for the trial, w...

SmallCaps ZLD 1 year ago
Zelira, PolyNovo prove even a pandemic can’t stand in the way of good clinical results

In proof that biotechs will deliver market returns even during a pandemic, two companies this morning have issued clinical trial results and watched their share prices rocket. Pot stock Zelira Therapeutics (ASX:ZLD) has received the full re...

Stockhead ZLD 1 year ago
Dr Boreham’s Crucible: Zelira’s share price could wake up once sales of its pot-based insomnia drug start

Zelira Therapeutics (ASX:ZLD) chief Dr Richard Hopkins confirms what your columnist suspected was a self-serving myth perpetuated by overzealous users of the intoxicating herb: no one has ever been recorded as overdosing on cannabis over mi...

Stockhead ZLD 1 year ago
Zelira updates on trial in patients on opioid treatment

Medicinal cannabis company Zelira Therapeutics (ASX:ZLD) says its Phase 1 Dose Escalation Trial in patients on long-term opioid treatment is now fully enrolled.

BiotechDispatch ZLD 1 year ago
Cannabis: Another German importer wants Little Green Pharma’s products

Little Green Pharma (ASX:LGP) announced a new export partner — and it happens to be the only company covering the entire medicinal cannabis production chain. Berlin-based Deutsche Medizinalcannabis (Demecan) will import and sell LGP’s Class...

Stockhead ZLD 1 year ago
Zelira is worshipping at the FDA altar hoping it will smite enemies

Two years ago Zelira (ASX:ZLD) — then Zelda — was set to invade the German market, planning to storm the walls with unregistered marijuana products that had a little bit of clinical data behind them, data which would be the reason for a big...

Stockhead ZLD 1 year ago
Health: Compumedics wins FDA approval for its brain scanners, leaps 20pc

Another ASX small cap has won the blessing of the Food and Drug Administration (FDA) for its products enter the US market. This morning it was Compumedics (ASX:CMP). Its signature product, the Orion LifeSpan Magnetoencephalography single De...

Stockhead ZLD 1 year ago
Zelira Therapeutics completes capital raise

Medicinal cannabis company Zelira Therapeutics (ASX:ZLD) has completed a placement of 91,770,000 fully-paid ordinary shares at a share price of $0.05 to Australian and International investors.

BiotechDispatch ZLD 1 year ago